Recruiting transgender men in the Southeastern United States for genital microbiome research: Lessons learned (Q30429): Difference between revisions
Jump to navigation
Jump to search
Superraptor (talk | contribs) (Added [en] label: Recruiting transgender men in the Southeastern United States for genital microbiome research: Lessons learned) |
Superraptor (talk | contribs) (Added [en] alias: Recruiting transgender men in the Southeastern United States for genital microbiome research) |
||
| aliases / en / 0 | aliases / en / 0 | ||
Recruiting transgender men in the Southeastern United States for genital microbiome research | |||
Latest revision as of 17:27, 10 November 2024
No description defined
- Recruiting transgender men in the Southeastern United States for genital microbiome research: Lessons learned.
- Recruiting transgender men in the Southeastern United States for genital microbiome research
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Recruiting transgender men in the Southeastern United States for genital microbiome research: Lessons learned |
No description defined |
|
Statements
Transgender men (TGM) are underrepresented in genital microbiome research. (English)
BACKGROUND (English)
Copyright: © 2024 Van Gerwen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (English)
2024
Our prospective study in Birmingham, AL investigated genital microbiota changes over time in TGM initiating testosterone, including the development of incident bacterial vaginosis (iBV). (English)
BACKGROUND (English)
Copyright: © 2024 Van Gerwen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (English)
2024
Here, we present lessons learned from recruitment challenges encountered during the conduct of this study. (English)
BACKGROUND (English)
Copyright: © 2024 Van Gerwen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (English)
2024
Inclusion criteria were assigned female sex at birth, TGM or non-binary identity, age ≥18 years, interested in injectable testosterone but willing to wait 7 days after enrollment before starting, and engaged with a testosterone-prescribing provider. (English)
METHODS (English)
Copyright: © 2024 Van Gerwen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (English)
2024
Exclusion criteria were recent antibiotic use, HIV/STI infection, current vaginal infection, pregnancy, or past 6 months testosterone use. (English)
METHODS (English)
Copyright: © 2024 Van Gerwen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (English)
2024
Recruitment initiatives included community advertisements via flyers, social media posts, and referrals from local gender health clinics. (English)
METHODS (English)
Copyright: © 2024 Van Gerwen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (English)
2024
Between February 2022 and October 2023, 61 individuals contacted the study, 17 (27.9%) completed an in-person screening visit, and 10 (58.8%) of those screened were enrolled. (English)
RESULTS (English)
Copyright: © 2024 Van Gerwen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (English)
2024
The primary reasons for individuals failing study screening were having limited access to testosterone-prescribing providers, already being on testosterone, being unwilling to wait 7 days to initiate testosterone therapy, or desiring the use of topical testosterone. (English)
RESULTS (English)
Copyright: © 2024 Van Gerwen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (English)
2024
Engagement of non-White TGM was also minimal. (English)
RESULTS (English)
Copyright: © 2024 Van Gerwen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (English)
2024
Despite robust study inquiry by TGM, screening and enrollment challenges were faced including engagement by TGM not yet in care and specific study eligibility criteria. (English)
CONCLUSION (English)
Copyright: © 2024 Van Gerwen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (English)
2024
Excitement among TGM for research representation should be leveraged in future work by engaging transgender community stakeholders at the inception of study development, particularly regarding feasibility of study inclusion and exclusion criteria, as well as recruitment of TGM of color. (English)
CONCLUSION (English)
Copyright: © 2024 Van Gerwen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (English)
2024
These results also highlight the need for more clinical resources for prescribing gender-affirming hormone therapy, especially in the Southeastern US. (English)
CONCLUSION (English)
Copyright: © 2024 Van Gerwen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (English)
2024
Olivia T (English)
Van Gerwen (English)
OT
Z Alex (English)
Sherman (English)
ZA
Emma Sophia (English)
Kay (English)
ES
Jay (English)
Wall (English)
J
Joy (English)
Lewis (English)
J
Isaac (English)
Eastlund (English)
I
Keonte J (English)
Graves (English)
KJ
Saralyn (English)
Richter (English)
S
Angela (English)
Pontius (English)
A
Kristal J (English)
Aaron (English)
KJ
Krishmita (English)
Siwakoti (English)
K
Ben (English)
Rogers (English)
B
Evelyn (English)
Toh (English)
E
Jacob H (English)
Elnaggar (English)
JH
Christopher M (English)
Taylor (English)
CM
Nicholas J (English)
Van Wagoner (English)
NJ
Christina A (English)
Muzny (English)
CA
14 August 2024
12 August 2024
The authors have declared that no competing interests exist. (English)